Biotech Values

[dewophile]

There's a huge difference between confidence and knowing

can't argue this point - and in thinking about this some more monetizing lovenox without knowing how long sole generic status would be maintained may have been difficult if mnta and nvs (or whatever other party interested in purchasing the m-enox cash flow) didn't see eye to eye on a probability-adjusted scenario

That's why, rightly or wrongly, I view today's offering news as a bird in the hand deal

it very well may be. but on the confidence meter the timing doesn't sit well with me. one would think the stock in 6 months without another generic approved would have to be 20% higher. then again from a big picture standpoint waiting 6 months to move the business forward to try and get 20% more for a modest sized offering, while taking even a small chance that teva gets approved and potentially killing any equity financing at a palatable price may have been what management was weighing

i happen to be of the opinion no one really knwos what is up with tenox - perhaps not even teva since immunogenicity does seem to be the difficult hurdle for lovenox given the risk of HIT and the high safety bar the FDA has had ever since vioxx (and that is where they are held up by their own admission)